Table 2. Observed and expected numbers and SIRs with 95% confidence intervals for third non-breast cancers after bilateral breast cancer.
| Site of TNBC | Observed numbers | Expected numbers | SIR | 95%CI |
|---|---|---|---|---|
| Head and neck | 18 | 9 | 2.0 | 1.2–3.2 |
| Thyroid | 3 | 2 | 1.4 | 0.29–4.6 |
| Oesophagus | 5 | 6 | 0.84 | 0.27–2.1 |
| Stomach | 25 | 12 | 2.1 | 1.4–3.2 |
| Pancreas | 15 | 12 | 1.2 | 0.67–2.0 |
| Liver, intrahepatic bile ducts and biliary tract | 7 | 5 | 1.5 | 0.60–3.2 |
| Colorectal | 91 | 74 | 1.2 | 0.99–1.5 |
| Digestive organs, other | 5 | 3 | 1.6 | 0.52–3.9 |
| Lung | 77 | 35 | 2.2 | 1.7–2.8 |
| Soft tissue | 8 | 2 | 3.6 | 1.5–7.3 |
| Melanoma of skin | 25 | 18 | 1.4 | 0.89–2.1 |
| Non-melanoma skin | 80 | 50 | 1.6 | 1.3–2.0 |
| Ovarian | 33 | 14 | 2.3 | 1.6–3.4 |
| Endometrial | 58 | 22 | 2.6 | 2.0–3.4 |
| Cervix uteri | 5 | 5 | 0.97 | 0.31–2.4 |
| Vulva | 5 | 4 | 1.1 | 0.36–2.8 |
| Female genitalorgans, othera | 6 | 1 | 4.6 | 1.7–10.4 |
| Urinary bladder | 19 | 15 | 1.3 | 0.78–2.0 |
| Kidney | 20 | 8 | 2.4 | 1.5–3.8 |
| Brain | 2 | 4 | 0.50 | 0.06–2.1 |
| Haematological | 48 | 33 | 1.5 | 1.1–1.9 |
| All TNBCsb | 582 | 363 | 1.6 | 1.5–1.7 |
Abbreviations: CI=confidence interval; SIR=standardised incidence ratio; TNBC=third non-breast cancer.
Bold entries denote statistical significance.
a
Included, not otherwise specified and vagina.
b
Included others than the specific sites denoted: renal pelvis (2 observed cases), thymus (1 observed case), eye (3 observed cases), other or unspecified sites (4 observed cases), primary sites unknown (10 observed cases) and benign brain tumour (7 observed cases).